key: cord-0912407-0rvqww6v
authors: Mungmunpuntipantip, Rujittika; Wiwanitkit, Viroj
title: Antibody response to SARS‐CoV‐2 vaccination, previous SARS‐CoV‐2 infection, and change to single‐dose vaccination
date: 2021-08-12
journal: J Med Virol
DOI: 10.1002/jmv.27263
sha: 76486837f7dcecb5bcea5d140d183653040139c0
doc_id: 912407
cord_uid: 0rvqww6v

Dear Editor, we would like to share ideas on "Antibody response to SARS-CoV-2 vaccination is extremely vivacious in subjects with previous SARS-CoV-2 infection [1]." Callegaro et al. concluded that "In SARS-CoV-2 naturally infected individuals a single mRNA vaccine dose seems sufficient to reach immunity. Modifying current dosing schedules would speed-up vaccination campaigns [1]." We agree with this idea. In addition, giving a vaccine to a person with previous COVID-19 requires a careful consideration on efficacy and safety. A recent report show that there is a significant change of blood viscosity in a vaccine recipient with previous COVID-19 and it might imply a higher risk for develop hyperviscosity problem [2]. Hence, in addition to increase effectiveness in COVID-19 vaccine distribution during the present pandemic, a change to a single dose vaccination can also increase safety among persons who have or likely to have previous COVID-19. Regarding the time point of vaccination post COVID-19, the single dose vaccination should be given at 3 months after the recovery. At that period, there is a decay of post infection immunity [3], hence, the vaccination will promote immunity and it will be safe from rheological adverse effect. To derive a conclusion and make it in practice, further animal, such as non-human primate, studies should be performed to demonstrate the efficacy of single dose vaccine in previously SARS-CoV-2 infected animals. This article is protected by copyright. All rights reserved.

All the authors declare that there are no conflicts of interests. 

Antibody response to SARS-CoV-2 vaccination is extremely vivacious in subjects with previous SARS-CoV-2 infection

Expected viscosity after COVID-19 vaccination, hyperviscosity and previous COVID-19

Dynamics of anti-SARS-CoV-2 IgG antibodies post-COVID-19 in a Brazilian Amazon population